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ABSTRACT
The gene encoding mt-tRNALeu(UUR), MT-TL1, is a
hotspot for pathogenic mtDNA mutations. Amongst
the first to be described was the 3302A.G transition
which resulted in a substantial accumulation in pa-
tient muscle of RNA19, an unprocessed RNA inter-
mediate including mt-16S rRNA, mt-tRNALeu(UUR)
and MTND1. We have now been able to further
assess the molecular aetiology associated with
3302A.G in transmitochondrial cybrids. Increased
steady-state levels of RNA19 was confirmed, al-
though not to the levels previously reported in
muscle. This data was consistent with an increase in
RNA19 stability. The mutation resulted in decreased
mt-tRNALeu(UUR) levels, but its stability was
unchanged, consistent with a defect in RNA19
processing responsible for low tRNA levels. A
partial defect in aminoacylation was also identified,
potentially caused by an alteration in tRNA struc-
ture. These deficiencies lead to a severe defect in
respiration in the transmitochondrial cybrids, con-
sistent with the profound mitochondrial disorder
originally associated with this mutation.
INTRODUCTION
Mutations of mitochondrial DNA (mtDNA) are responsible
for a broad range of diseases usually affecting multiple
sites, particularly the central nervous system, muscle and
retina. In some cases disease is limited to one tissue, even
a single cell type (1). Although we continue to find new
mutations in mtDNA, our understanding of how mitochon-
drial tRNA mutations cause their cellular defect has not
grown to the same extent.
In the present work, we further studied the 3302A>G muta-
tion of the MT-TL1 gene that affects the 30 terminal part
of the encoded mt-tRNALeu(UUR) (2). This mutation is
rare (2,3) and causes a severe myopathy with respiratory
insufficiency. The rarity of this mutation and severity of its
phenotype are in keeping with the fact that this nucleotide
is highly conserved among mammals (4). Our previous stud-
ies showed that the 3302A>G mutation probably interferes
with processing of an RNA precursor, RNA 19, that contains
16S rRNA, mt-tRNALeu(UUR) and MTND1, and also showed
that different precursor processing pathways are present in
skeletal muscle and fibroblasts (2). Cytoplasts generated
from fibroblasts of the patient were fused to 143B osteosar-
coma rho0 cells and the cybrid clones were used in the
present study to analyse in detail the molecular consequences
of the mutation.
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MATERIALS AND METHODS
Cell culture, generation of cybrid clones and
measurement of proliferation rate
Cybrids carrying the 3302A>G mutation were generated by
fusion of enucleated fibroblasts from the index patient with
143B rho0 cells (5). Cells were grown in DMEM, 5% fetal
calf serum (FCS), 110 mg/ml sodium pyruvate, 50 mg/ml
uridine and 1% penicillin/streptomycin at 37C and 5%
CO2. Using the cylinder method 60 individual cell clones
were isolated and initial analysis for level of heteroplasmy
showed that all clones analysed carried 85% mutant load,
the same level that was present in the patient’s fibroblasts.
To generate clones with higher levels of heteroplasmy, the
bulk cybrid population was cultivated in the presence of
100 ng/ml ethidium bromide (EtBr) for 2 weeks. Subse-
quently, EtBr was removed and cells were allowed to
increase their mtDNA content for 2 weeks before being
cloned once more. Again, individual clones were generated
and analysed for their mutant content.
The following control cell lines cultivated in the same
medium were included in further experiments: the parental
143B cells, 143B rho0 cells repopulated with wild-type
(wt)-mtDNA from fibroblasts of an unrelated individual (con-
trol 1), 143B rho0 cells repopulated with wt-mtDNA from
the patient’s healthy maternal aunt (control 2), 143B rho0
cells repopulated with 100% 3243A>G mtDNA (A3243G
100%), 143B rho0 cells repopulated with 100% wt-mtDNA
obtained during fusion experiments aimed at generating a
cybrid clone containing the 3243A>G MELAS mutation
(A3243G wt). The A3243G clones were kindly given to us
by Dr Eric Shoubridge, the fibroblast fusions were carried
out by Dr Karl Morton.
To analyse cell proliferation, cells were seeded at a density
of 5000 cells per cm2, cultivated with daily changes of
growth medium, harvested by trypsinization at selected
time points and counted using a CASY1 cell counter (Scha¨rfe
System GmbH, Reutlingen, Germany). This device also
measures cell size distribution by pulse area analysis, making
it possible to discriminate living from dead cells.
To analyse the degradation rate of mitochondrial
transcripts, 2 · 105 cells were pre-seeded in 60 mm dishes.
The medium was changed after 24 h and cybrids were
cultivated in EtBr (50 ng/ml) for up to 48 h before extraction
of RNA.
Fibroblasts of healthy control individuals were cultivated
in DMEM supplemented with 10% FCS, 1· non-essential
amino acids, 2 mM L-glutamine and 1% penicillin/
streptomycin at 37C and 5% CO2. Primary human myoblast
cultures were established from muscle samples obtained from
healthy individuals undergoing orthopaedic hip surgery using
standard techniques (6), which had been approved by the
local ethics committee of the Medical Faculty of the Univer-
sity of Ko¨ln. Myoblasts were cultivated in Ham’s F10 medium
supplemented with 20% FCS, 2% chicken embryo extract,
2 mM L-glutamine and 1% penicillin/streptomycin at 37C
and 5% CO2. Myoblasts were fused to multi-nucleated
myotubes by changing to DMEM supplemented with 4%
horse serum, 100 mg/ml human transferrin, 10 mg/ml human
insulin, 4 mM L-glutamine and 1% penicillin/streptomycin.
Myotubes were identified by the presence of a minimum
number of three nuclei within each fused cell when inspected
under the microscope.
Analysis of heteroplasmy levels in different
cybrid clones
The level of mutation load was determined using a radio-
active PCR/RFLP (restriction fragment length polymor-
phism) method. Total DNA was extracted from individual
cell populations as described previously (2). For the
3302A>G mutation a 725 bp fragment encompassing the
mutation site was amplified with the forward primer mt-
3232-s: 50-TAAGATGGCAGAGCCCG-30 and the reverse
primer mt-3957-as: 50-TCGGGCGTATTCGATGTT-30. Sam-
ples were subjected to 30 cycles of amplification [3 min at
94C; 45 s at 94C, 1.5 min at 57C, 1.5 min at 72C
(30·), final extension at 72C for 7 min]. After renewed addi-
tion of 30 pmol of each primer, 5 mCi [a-32P]dCTP (5000 Ci/
mmol; Hartmann Analytics, Braunschweig, Germany) and
1 U Taq polymerase (Promega, Heidelberg, Germany), the
PCRs were subjected to an additional cycle of amplification.
Labelled amplicons were precipitated and equal amounts
(2000 counts) digested with 10 U MseI (New England Bio-
labs, Frankfurt am Main, Germany). Restriction fragments
were separated on 3.3% non-denaturing polyacrylamide
gels, dried on a support and analysed with ImageQuant
software following exposure to a PhosphorImager (Molecular
Dynamics, Krefeld, Germany). Three MseI sites are present
in the wt product generating fragments of 32, 35, 172 and
486 bp. The 3302A>G mutation destroys an MseI site
and results in the three remaining fragments of 32, 172 and
521 bp.
An analogous method was employed to analyse the
A3243G wt or mutant cybrids using the following primers:
mt-2928-s 50-CCTAGGGATAA GCGCA-30 and mt-3305-as:
50-TAATACGACTCACTATATTGTTAAGAAGAGGAATTG-
30 and HaeIII digestion as described previously (7). Resolu-
tion of digestion products was carried out on 8%
non-denaturing polyacrylamide gels.
Biochemical characterization of cybrid clones
Cells were grown until they were almost confluent, and the
medium was changed the day before the measurements.
Cells were harvested by trypsinization, centrifuged and
washed twice in phosphate-buffered saline (PBS). The final
cell pellet contained 106–107 cells and was resuspended at
a density of 104–105 cells/ml in PBS. The cellular density
of the suspension was evaluated by automated counting
(CASY, Scha¨rfe Systems, Reutlingen, Germany) while the
protein content was determined by Bradford assay (Bio-
Rad, Mu¨nchen, Germany). This cell suspension was then
used in part for oxygen consumption assays and was in part
frozen for further spectrophotometric studies. Oxygen con-
sumption studies were done using two Clark chambers
(Hansatech, King’s Lynn, UK), recording the intact cell
respiration rate and then, after permeabilization with digito-
nine, the rates for pyruvate (+malate), malate (+glutamate),
succinate and glycerol-3-phosphate as substrates, as
described in detail previously (8).
Spectrophotometric measurements were performed using a
Beckmann DU-600 spectrophotometer (Beckmann Instruments,
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Fullerton, CA, USA) for determination of the enzymatic
activities of succinate–cytochrome c reductase (SCCR,
CII+III), decylubiquinol–cytochrome c reductase (QCCR, C
III), cytochrome c oxidase (COX, C IV), as well as citrate
synthase (CS) and lactate dehydrogenase (LDH) as reference
enzymes (8).
Analysis of mitochondrial transcripts, tRNA
levels and properties by northern blotting
Total RNA was isolated from frozen skeletal muscle tissue of
the patient and of muscle samples obtained from healthy indi-
viduals, ground to a fine powder in liquid nitrogen, and from
cultured cells (cybrids, fibroblasts, myoblasts, myotubes;
2 · 106 cells) using Trizol reagent (Invitrogen, Karlsruhe,
Germany). For the analysis of mRNA and precursor RNAs,
5 mg of total RNA was separated through 1.2% agarose
gels containing 6.5% formaldehyde, 1· MOPS buffer
(40 mM morpholinosulfonic acid, 10 mM sodium acetate
and 1 mM EDTA, pH 7.0) and 1· MOPS as a running buffer.
Separated samples were capillary blotted on to GeneScreen-
plus membrane (Perkin Elmer, Zaventem, The Netherlands)
in 10· SSPE and immobilized by UV fixation. For the
northern-blot analysis of polyadenylated RNA species
poly(A) RNA was isolated from 100 mg of total RNA using
the Oligotex mRNA Mini Kit (Qiagen, Hilden, Germany).
The total yield from the extraction procedure was subjected
to northern-blot analysis as described above.
For quantification of tRNAs and determination of RNA
length, samples of 0.25–2 mg of total RNA were denatured
(90C for 5 min) and separated on 13% denaturing polyacry-
lamide gels containing 8 M urea, using 1· TBE as a running
buffer (termed neutral to distinguish from acidic gels). Sepa-
rated samples were electroblotted onto GeneScreen-plus
membrane in 0.25· TBE and immobilized by UV fixation.
For the analysis of tRNA structure, unheated samples of
0.5 mg total RNA were subjected to electrophoresis through
a 8% non-denaturing polyacrylamide gel using 1· TBE as
gel and running buffer. Blotting and immobilization was
performed as before.
To investigate aminoacylation of tRNAs, we extracted total
RNA from cultured cells under acidic conditions as described
previously (9). RNA isolated using Trizol reagent was kept
on ice during the procedure and the final RNA pellet was
resuspended in 0.3 M sodium acetate (pH 4.5) and 1 mM
EDTA. Total acidic RNA (10 mg) was electrophoresed
through a 6.5% acidic, denaturing polyacrylamide gel (20 ·
43 cm2, 1 mm thickness) containing 8 M urea and 0.1 M
sodium acetate/0.1 M acetic acid, pH 5.0, as running buffer
at 4C and 30 mA over 48 h. Final running distance of xyle-
necyanol was 23 cm. Deacylation of individual RNA samples
was carried out in 0.3 M Tris–HCl, pH 9.0, at 75C for
15 min. Separated samples were electroblotted and immobi-
lized onto GeneScreen-plus membranes as described above.
Templates for in vitro transcription were amplified by PCR
from a synthetic single stranded 144mer DNA encoding a
hammerhead ribozyme downstream of a T7-promotor and
followed by the sequence of wt human mt-tRNALeu(UUR) or
the 3302A>G mutation (10). Upon transcription with T7-
RNA polymerase, the hammerhead ribozyme cleaves at its
designated target site to release the tRNA sequence with a
50-hydroxyl end (11). After purification over a 12% 8 M
urea PAGE, transcripts were passively eluted by agitation
in 0.5 M NH4OAc. 5
0-Labelling with ATP and T4-PNK and
subsequent purification by PAGE were performed as
described previously (12).
Regions of mtDNA encompassing various mRNA and
tRNA genes amplified by PCR were used as probes for the
northern blots. As template for the PCRs, DNA derived
from 143B control cells was used. The mRNAs probes
were amplified using the following forward and reverse
primers.
For ND1: mt-3384-s: 50-AATTCTAGGCTATATACAA-
C-30 and mt-7395-as: 50-ATCCATATAGTCACTCCA-30,
which was digested to give specific probes for ND1, ND2
and COI; for COI: mt-5907-s: 50-TAAGGGAGGGTAGA-
CACG-30 and mt-6299-as: 50-TCGCCGACCGTTGACTAT-
30. For 28S rRNA a 497 bp fragment was amplified using
the forward primer 50-AAGATGGTGAACTATGCCTG-30-
and reverse primer 50-GCAGGTGAGTTGTTACACAC-30.
Transfer RNA probes were generated as follows:
for tRNALeu(UUR): mt-3232-s: 50-TAA GAT GGC AGA GCC
CG-30 and mt-3305-as: 50-TAA TAC GAC TCA CTA
TAT TGT TAA GAA GAG GAA TTG-30; for tRNAVal:
mt-1602-s: 50-CAGAGTGTAGCTTAACACAAA-30 and
mt-1670-as: 50-TCAGAGCGGTCAAGTTAA-30; for
tRNALys: mt-8259-s: 50-TTACCCTATAGCACCCCCT-
30 and mt-8390-as: 50-ATACGGTAGTATTTAGTTGGG-30.
For the normalization of tRNAs to a non-mitochondrial
small RNA species blots were hybridized to a 5S rRNA
probe. The oligonucleotide 50-GGGTGGTATGGCCGTAG-
AC-30 (13) was end labelled using [g-32P]ATP (5000 Ci/mmol,
Hartmann Analytics, Braunschweig, Germany) and T4-
PNK. Purified PCR products (QIAquick PCR purification
columns, Qiagen, Hilden, Germany) were radiolabeled with
[a-32P]dCTP (5000 Ci/mmol; Hartmann Analytics, Braun-
schweig, Germany) by the random-primer method, and
unincoorporated nucleotides were removed from labelling
reactions by gel filtration through ChromaSpin columns
(Clontech, Heidelberg, Germany).
Hybridization was carried out at 65C (exceptions: 50C:
ND1, 55C: tRNALeu(UUR)) overnight in 10 ml of a solution
of 1% SDS, 10% dextran sulphate and 1 M NaCl containing
2 · 106 c.p.m. radiolabelled probe plus 4 mg sonicated sal-
mon sperm DNA. After hybridization, two 10-min washes
were performed at 45C–65C with 2· SSC, 0.1% SDS, fol-
lowed by a 3–10-min wash at 45C–65C with 0.1· SSC,
0.1% SDS. Blots were subjected to PhosphorImager analysis
and/or autoradiography.
RESULTS
Genotype, proliferation and mitochondrial activity in
cybrid clones
After treatment with and recovery from EtBr, last hot cycle
PCR analysis showed that 3 of 35 clones harboured the
3302A>G mutation at levels close to homoplasmy. One
clone carried the mutation at a much lower level (77%,
Supplementary Figure 1). All other clones were 85–95%
mutant. A clone containing the 3243A>G MELAS mutation
at 100% (3243 100%) was included in further experiments
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to allow comparison of two mutations affecting the same
tRNA. Proliferation rates for the clones containing high levels
of the mutated mtDNA showed no significant difference
when compared with the wild-type control strains (data not
shown).
Two cell lines were used to characterize extensively the
biochemical defect, parental 143B cells and clone 3 contain-
ing 98% of the 3302A>G mutation (Figure 1). In intact cells,
3302A>G cells showed a 6-fold reduction of respiration, from
4 to 0.6 fmol O2/cell · min, compared with parental 143B
cells. Oxidation of pyruvate, malate and succinate, measured
following permeabilization were severely reduced (to 10,
10 and 40% of mean control values, respectively), while
oxidation of glycerol-3-phosphate was similar to the control
(Figure 1A). Spectrophotometric assays of the activities
of Complexes II+III (SCCR), Complex III (QCCR) and
Complex IV (COX) of the mitochondrial respiratory chain
revealed marked deficiency of Complex (C) III and C IV,
while C II+III remained unchanged (Figure 1B). The clone
containing the mutation at 77% showed no respiration defect.
In conclusion, the 3302A>G mutation causes a dramatic
defect in respiratory chain function in 143B osteosarcoma
cybrid cells when present at high levels, as it did in skeletal
muscle of the patient (14).
Levels of mt-tRNALeu(UUR) in cybrid clones and
patients muscle
Densitometric analysis of a PAGE-northern blot showed that
tRNALeu(UUR) was reduced in clones bearing the 3302A>G
mutation (Figure 2A). This was more obvious in cells with
near homoplasmic levels of the mutation, where the amount
was <60% of controls, than in the clone with 77% hetero-
plasmy. The level of mt-tRNALeu(UUR) was even lower in
the 3243 100% clone (Figure 2), confirming earlier studies
with this mutation (15,16). In our initial analysis of the
patient’s muscle (2), the extraction procedure used (17) did
not allow recovery of small RNAs, thus no information was
available concerning tRNA levels in vivo. We now used a
different method to extract total RNA from the remainder
of the skeletal muscle biopsy that had been stored in liquid
N2 for almost 15 years. Analysis showed that the tRNAs
were still intact and yielded sharp bands (Supplementary
Figure 2, upper panel). The level of mt-tRNALeu(UUR) is
also reduced in the muscle of the patient when compared
with healthy controls (Supplementary Figure 2, lower
panel). This is seen when normalized to nuclear encoded
5S rRNA (Supplementary Figure 2, black bars), but becomes
especially evident when normalized to two other randomly
selected mitochondrial tRNAs, mt-tRNALys or mt-tRNAVal,
encoded on the same DNA strand (Supplementary Figure 2,
white and grey bars). As is often seen for randomly selected
human individuals, the variability between the two controls is
high, but still allows the conclusion that the 3302A>G muta-
tion leads to decreased levels of mt-tRNALeu(UUR) also in the
patient’s muscle, while interestingly a general increase of
other mitochondrial tRNAs is observed.
These findings suggest that either the rate of synthesis or
the stability of mt-tRNALeu(UUR) is impaired by the
3302A>G mutation.
Accumulation of the unprocessed precursor RNA19 and
stability of mt-tRNALeu(UUR)
The most profound finding in our initial description of
the patient was that the mutation at nt 3302 leads to a
dramatic, up to 1000-fold, accumulation of RNA19 in muscle
(2). This precursor transcript consists of the mt-tRNALeu(UUR)
flanked by 16S rRNA and ND1 mRNA (18). Northern-blot
analysis of cybrid cell RNA consecutively hybridized with
mt-tRNALeu(UUR) and ND1 mRNA probes (Figure 3) showed
that increased amounts of RNA19 were also present in the
cybrid cells containing the 3302A>G mutation at 77 and
98%, but at much lower levels than in the patient’s muscle.
Accumulation of RNA19 was also found in the clone bearing
the 3243A>G mutation at homoplasmic levels, confirming
earlier reports (18–21), however the ratio RNA19/ND1 was
clearly higher in the presence of the 3302A>G mutation.
Figure 1. Respiratory chain phenotype of cybrid cell lines. (A) Polarography.
Graphs show mean values and standard deviations for oxygen consumption of
143B control cells (white bars, n ¼ 10) and of cybrids containing the
3302A>G mutation at 98% (grey bars, n ¼ 3) in intact cells and
permeabilized cells respiring on the indicated substrates. (mal ¼ malate;
glu ¼ glutamate). (B) Respiratory chain complex activities. Graphs show
activities for SCCR—Complex II+III, QCCR—Complex III, COX—
Complex IV and CS as mitochondrial matrix marker. Graphs are mean
values and standard deviations for 143B control cells (white bars, n ¼ 5) and
cybrids containing the 3302A>G mutation (grey bars, n ¼ 3).
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In our earlier study, we also showed that RNA19 appears to
be cleaved by different pathways in skeletal muscle compared
with proliferating fibroblasts (2). This would lead to different
intermediates and we postulated that this might be the under-
lying mechanism explaining the striking tissue selectivity of
this mutation. When hybridized with a mt-tRNALeu(UUR)
probe (Figure 3), northern-blot analysis of skeletal muscle
RNA confirmed that RNA19 is predominantly cleaved
to a 1.07 kb intermediate, probably consisting of mt-
tRNALeu(UUR) + ND1 mRNA. In all other samples, including
human primary myoblasts, human myotubes and human
primary fibroblasts, in addition to the 143B clones, this
Figure 2. Determination of steady-state levels of tRNALeu(UUR) in cybrid clones. (A) Levels of tRNAs analysed by high-resolution PAGE followed by blot
hybridization in two control cell lines and the cybrid clone containing 77% of the 3302A>G mutation and 98% of the 3302A>G mutation, as well as a clone
containing the 3243A>G mutation (3243 100%). RNA was loaded in two concentrations in order to ensure linearity of the densitometric signal. (B) The
densitometric values for 1 mg of 143B RNA were arbitrarily set to 1.0 in order to get an estimate of the variability of the measurements. Upper panel: levels of
mt-tRNALeu(UUR) (black bars) and tRNAVal (grey bars) were normalized to nuclear encoded 5S rRNA; lower panel: Levels of mt-tRNALeu(UUR) were normalized
to tRNAVal.
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RNA species was virtually absent and instead a 1.6 kb
intermediate was present. Similar to RNA19, this intermedi-
ate, comprising tRNALeu(UUR) + 16S rRNA was especially
prominent in the clones containing mt-tRNALeu(UUR) muta-
tions. The resolution of the gel was insufficient to differenti-
ate between the mature ND1 mRNA and the muscle specific
precursor tRNALeu(UUR) + ND1 mRNA because of the small
difference in length, thus the ND1 probe only shows one band
in all samples. Levels of the mRNA for MTCOI were
similar in all cell lines, while the ND1 mRNA was slightly
increased in the clones containing high levels of the
3302A>G and 3243A>G mutations. Mitochondrial transcripts
were absent in 143B rho0 cells (right lane), as expected.
In conclusion, RNA19 accumulates in 143B cybrid cells
containing the 3302A>G mutation, however to a lesser degree
than in the patients muscle. The skeletal muscle specific
processing pattern for this transcript could only be observed
in vivo in mature muscle, and could not be recapitulated in
cultured cells, not even in differentiated primary human
myotubes.
We postulated earlier that accumulation of RNA19
could result in impaired release and synthesis of mature mt-
tRNALeu(UUR) (2) and might thereby explain decreased
steady-state levels of this tRNA. To study this question,
mtDNA transcription was blocked by EtBr and RNA decay
analysed over an 8 hr time period. In three independent
experiments, we found RNA19 to be more stable in the
clones containing the 3302A>G mutation compared with
either a control line or cells containing the 3243A>G
mutation. One experiment is shown in Figure 4; this demon-
strates that RNA19 does not display an exponential decay in
3302 cybrid cells, but appears to be stabilized after EtBr
treatment, leading to increased steady-state levels between
4 and 6 h. The half-life of the mature ND1 mRNA was
also found to be increased in the clone containing the
3302A>G mutation, whereas half-life of COX I mRNA was
similar (data not shown). Thus, our results suggest that the
3302A>G mutation does indeed cause a processing defect,
leading to an increased stability and, consequently, increased
steady-state levels of RNA19.
A decreased rate of RNA19 processing due to mutations of
mt-tRNALeu(UUR) may cause a protein synthesis defect, not
only due to lowered availability of the tRNA (loss of func-
tion), but also due to the accumulation of the precursor itself
[gain-of-function, (22)]. RNA19 could adversely affect
translation in two ways: If the 16S rRNA component is incor-
porated into the ribosome this may cause stalling of a result-
ing abnormal ribosome (18). Alternatively, polyadenylated
RNA19 may potentially be loaded onto mitoribosomes.
Although little is known concerning the structural require-
ments for mRNA binding in mammalian mitochondrial
ribosomes, polyadenylation seems to be important. We there-
fore analysed poly(A+)-RNA prepared from cybrid cell RNA
by northern blotting and found that RNA19 is indeed present
in higher amounts in the poly(A+)-fraction from cells contain-
ing the 3302A>G mutation than in cells containing the
3243A>G mutation or in control cells, especially when
compared with polyadenylated ND1 mRNA (Figure 5).
Figure 3. Analysis of mitochondrial transcript processing in cybrid clones, human skeletal muscle and primary human myoblasts, myotubes and fibroblasts.
Levels of the precursor transcript RNA19 and its processing intermediates as well as ND1 and COX I mRNA analysed by agarose gel electrophoresis followed by
blot hybridization. Samples were from two healthy human skeletal muscles (lanes 1 and 3), primary human myoblasts from these biopsies (lanes 4 and 5),
primary human myotubes differentiated in vitro from such myoblasts (lanes 6 and 7), primary human fibroblasts (lanes 8 and 9), control cell lines (143B, 3243
wt, lanes 10 and 12) and from the cybrid clone containing 77% of the 3302A>G mutation (lane 13), 98% of the 3302A>G mutation (lane 14), as well as from the
clone containing the A3243G mutation (3243 100%, lane 11). RNA from 143B rho0 cells was also loaded (lane 15). 5 mg of total RNA was loaded in each lane.
Probes used for hybridization are indicated on the right, RNA species identified on the left.
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In addition to sequestration in RNA19, reduced levels of
mt-tRNALeu(UUR) may be caused by an increased rate of
degradation due to destabilization of the tRNA structure
by the mutation. We measured degradation rate by analysing
the decay of tRNAs following inhibition of mtDNA transcrip-
tion by low concentrations of EtBr (Figure 6A). Inhibition
was maintained for 48 h and two independent experiments
showed identical results. Decay of mt-tRNALeu(UUR) was
compared with that of two other tRNAs encoded on the
same strand (tRNAVal and tRNALys). There were no obvious
differences in tRNA decay in clones containing high levels
of the 3302A>G or 3243A>G mutation nor between degrada-
tion rate for mt-tRNALeu(UUR), tRNAVal and tRNALys situated
upstream and downstream of the mutated tRNA (Figure 6B).
For the 3243A>G mutation, this is in contrast to the work of
(16), who however used HeLa cybrids. Differences in pheno-
typic consequences of the same mutation in different nuclear
backgrounds have been discussed extensively (22).
In conclusion, the 3302A>G mutation leads to decreased
levels of the tRNA, but this is mostly due to decreased release
from its precursor RNA19 and not due to decreased stability
caused by the mutation.
Aminoacylation levels and structural changes
To investigate the possibility of additional, qualitative
changes in mt-tRNALeu(UUR) function, we analysed the
level of tRNA aminoacylation. RNA was extracted under
acidic conditions and separated on a 6.5% acidic, denaturing
polyacrylamide containing 8 M urea (Figure 7). Deacylated
RNA samples of all cell lines plus a mixture of native and
deacylated RNA from 143B cells were also loaded to
facilitate identification of the two species. Surprisingly, we
found that the tRNALeu(UUR) carrying the 3302A>G mutation
migrated considerably slower than the wt-tRNA or the tRNA
Figure 4. Determination of the half-life of RNA19 and ND1 mRNA in cybrid clones treated with EtBr for up to 8 h. Decay of mitochondrial transcripts was
analysed by agarose gel electrophoresis followed by blot hybridization to a probe for ND1 mRNA in isogenic control cells containing 100% wt-mtDNA (3243
wt), in the cybrid clone containing the 3302A>G mutation (3302 98%), as well as in the clone containing the 3243A>G mutation (3243 100%).
Figure 5. Analysis of polyadenylation of RNA19. Polyadenylation of RNA19
was analysed by agarose gel electrophoresis of total RNA (5 mg) and
poly(A+)-RNA (the total yield from 100 mg of total RNA) in 143B control
cells, in the cybrid clone containing the 3243A>G mutation, as well as in the
clone containing 98% of the 3302A>G mutation. Probes used for hybridiza-
tion are indicated on the right, RNA species identified on the left.
6410 Nucleic Acids Research, 2006, Vol. 34, No. 22
Figure 6. Determination of the half-life of mitochondrial tRNAs in cybrid clones treated with EtBr for up to 48 h. (A) Decay of mitochondrial tRNAs was
analysed by high-resolution PAGE followed by blot hybridization in 143B control cells, in the cybrid clone containing 98% of the 3302A>G mutation, as well as
in the clone containing the 3243A>G mutation (3243 100%). RNA (0.5 mg) was loaded in triplicate per sample in order to minimize data acquisition errors of the
signals. (B) Densitometric data for tRNALeu(UUR), tRNAVal and tRNALys were normalized to nuclear encoded 5S rRNA.
Nucleic Acids Research, 2006, Vol. 34, No. 22 6411
carrying the 3243A>G mutation. In the clone containing the
mutation at 77%, the small amounts of deacylated wt-tRNA
are not visible, thus only 3 bands can be seen. Another fast
migrating RNA species of unknown identity (?) is always
seen in the clone containing the 3243A>G mutation, in
143B cells after alkaline treatment, but never in the clones
containing the 3302A>G mutation.
The ratio of aminoacylated to non-acylated tRNA is
considerably lower in both the 77 and 98% clone for the
3302A>G mutation (50:50), compared with wt-143B cells
(85:15, ratios calculated from three independent gels). It
has been shown before that the level of aminoacylation of
the tRNA carrying the 3243A>G mutation is also decreased
(15), and this is confirmed by our data.
The retarded migration induced by the 3302A>G mutation
could be due to (i) altered length resulting from misprocess-
ing, (ii) altered charge or (iii) altered structure, resulting
either directly from the change of the primary sequence or
from changes in post-transcriptional modifications. To
distinguish between these possibilities, RNA was isolated
under neutral conditions to split off the amino acid and anal-
ysed under different gel conditions. In addition, run-off
transcripts with the wt or the 3302A>G sequence were gener-
ated in vitro, were phosphorylated at the 50 end and run
together with RNA from cybrid cells (Figure 8). Acidic,
urea containing gels showed that introducing the mutation
into in vitro transcripts alone was sufficient to cause the
retarded migration, hence the 3302A>G change of the primary
sequence in tRNALeu(UUR) leads already to a structural change
relevant for its electrophoretic mobility (Figure 8A). Cellular
tRNAs comigrate with the 50-phosphorylated in vitro tran-
scripts. The 50-phosphate group, which increases the molecular
weight of the tRNA and adds negative charge, is sufficient to
slow down migration, but not to the extent induced by the
3302A>G mutation. This, as well as the fact that the
3243A>G mutation causes a similar change in nucleotide com-
position, but causes no difference in migration seen in the
aminoacylation experiment (Figure 7), argues against altered
charge being the reason for different mobility.
Under neutral, urea containing conditions, no migration
difference between wt and mutated tRNA can be observed,
and the clone containing 77% of mutated tRNA displays
only one band, arguing against different lengths being the
reason for different mobility (Figure 8B). Cellular tRNAs
migrate slightly faster than in vitro transcripts, thus they
seem to be more compact under these conditions.
Finally, non-denaturing gels which do not contain urea
allowing at least partial folding of the tRNAs show again a
retardation introduced by the mutation, and consequently
the clone containing 77% of mutated tRNA displays two
bands again (Figure 8C). Similar shifts in acidic, urea
containing as well as neutral gels have been found recently
in tRNALys containing the 8296A>G mutation (23).
In conclusion, the 3302A>G mutation causes structural
changes which may be the reason for the impairment of
charging with amino acid.
DISCUSSION
Our data shows that, at levels close to homoplasmy, the
3302A>G mutation in mt-tRNALeu(UUR) leads to a severe
biochemical defect in cybrid cells, as it did in the patient’s
muscle. This defect appears due to a combination of factors
including (i) a processing defect causing accumulation of
the precursor RNA19, probably leading to (ii) a decreased
steady-state level of mt-tRNALeu(UUR), (iii) a change in
tRNA structure, and (iv) a partial decrease in aminoacylation,
possibly due to this structural change.
The decreased steady-state level of mt-tRNALeu(UUR) is not
due to destabilization of the mutated tRNA, as shown
for mutations in the tRNASer(UCN) (24) or tRNAIle (25).
Instead, it is due to a lowered rate of release from the precur-
sor RNA19 that accumulates in cybrid cells, albeit to a lesser
extent than was seen in the patient’s muscle. Whether RNA19
induces ‘gain-of-function’ abnormalities such as becoming
part of ‘pseudoribosomes’ due to incorporation of its 16S
moiety (18), or being misread as an mRNA and thus blocking
ribosomes (26) remains uncertain. The fact that RNA19 also
accumulates in the clone containing the 3302A>G mutation at
77% (Figure 3), which however showed no defect in respira-
tion, rather argues against a gain-of-function, at least at these
steady-state levels of this precursor.
The 3302A>G mutation is close to the 30 terminus of the
tRNA, raising the possibility that it may impair recognition
and/or cleavage by an RNase Z-like activity perhaps similar
to that identified recently (27). Proximity to the 30 cleavage
Figure 7. Aminoacylation levels in cybrid clones. Degree of aminoacylation of mt-tRNALeu(UUR) in 143B cells, in the cybrid clones containing 77 or 98% of the
3302A>G mutation as well as in the clone containing the 3243A>G mutation (3243 100%). RNA was isolated from cells and separated by PAGE under acidic
conditions. Deacylated RNA samples of all cell lines and a mixture of acylated and deacylated RNA from 143B cells (first lane) were also loaded in order to
facilitate identification of the two species.
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site is not, however, a requirement for impairing the
endonucleolytic step, since it was shown that the mutations
3243A>G, 3271T>C and 3302T>C all lead to the accumula-
tion of RNA19 in vivo in biopsy samples of patients present-
ing with the mitochondrial myopathy, encephalopathy,
lactacidosis, stroke (MELAS) syndrome (28). These authors
showed that RNA19 molecules containing these mutations
are more abundant in RNA samples than was predicted
from the levels of DNA heteroplasmy suggesting that
processing may be affected by mutations throughout the
tRNA. Finally, artificial RNA molecules containing these
and other mutations were tested in vitro as substrates for a
30-tRNAse activity purified from HeLa cell mitoplasts. The
3302A>G mutation led to a decrease in Vmax, but not for
the Km of the cleavage process (29). Such in vitro studies
had also shown earlier that the 3243A>G mutation leads to
severe impairment of processing of an artificial RNA19 at
the 50 end by mtRNAse P as well as nRNAse P, whereas
RNA19 containing the 3302A>G construct was much less
affected (30). Thus, both mutations cause processing defects,
at both termini for 3243A>G and at the 30 end for 3302 A>G.
Alteration of secondary and/or tertiary structure by the
3302A>G mutation was identified using a combination of
electrophoretic techniques as a second possible mechanism
involved in pathogenesis, besides lowered levels of
mt-tRNALeu(UUR). Altered length due to misprocessing,
altered charge due to the change in primary sequence or
altered post-transcriptional modifications were excluded by
comparing running properties of the native tRNAs containing
the 3302A>G with those containing the 3243A>G mutation
or in vitro transcripts, respectively (Figure 8). An altered
structure caused by the 3302A>G mutation was rather
unexpected, since although 3302A>G weakens the second
(U2/A71) base-pair in the acceptor stem, leading to a G/U
wobble pair, the stabilizing effect of the G1/C72 base pair
should prevent important ‘breathing’ of this region (29).
Unfortunately, detailed structural probing assays on in vitro
transcribed substrates using various endonucleases was
difficult for technical reasons at sites so close to RNA termini.
We postulate that the structural change in mt-tRNALeu(UUR)
interferes with charging of leucine by the Leucyl-tRNA-
synthetase (LeuRS). This leads to a lower ratio of acylated
versus deacylated tRNA (Figure 7), which results in decreased
availability of Leu-tRNALeu(UUR) molecules in the 98% clone
at levels 30% of that seen in control cells, when taking into
account the decreased levels of the tRNA as well. In addition,
although these molecules are charged, they still may have a
structure that cannot be recognized appropriately by the
Figure 8. Analysis of tRNA structure, length and charge by different PAGE methods and northern blotting. RNA samples isolated under neutral conditions from
cell lines in order to split off the amino acid were run together with run-off transcripts with the wt or 3302A>G sequence, phosphorylated (IVT P) at the 50 end or
non-phosphorylated (IVT) under different conditions. Gels were blotted and probed with a probe for tRNALeu(UUR). (A) Urea containing, acidic conditions. (B)
Urea containing, neutral conditions. (C) Native, neutral conditions.
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ribosome. The charging defect could either be due to a directly
impaired interference of the LeuRS with the structurally altered
tRNA (31) or primarily due to impaired post-transcriptional
modification followed by impaired recognition by LeuRS.
Our finding that introducing the mutation into in vitro
transcripts is sufficient to alter the structure of the tRNA
(Figure 8) supports the first possibility, as well as the fact
that the small amounts of wt-Leu-tRNALeu(UUR) in the 77%
clone (Figure 7) can obviously rescue the defect.
Poor aminoacylation has also been shown for the 3243A>G
mutation in both, lung carcinoma cybrids (21) and 143B cells
(15). Secondary and/or tertiary structural alterations with
poor aminoacylation, alone or in combination with deficien-
cies of methylation of 3239G (32) and modification of uridine
at the first position of the anticodon (16) were suggested to be
the ultimate reason for impaired translation initiation, causing
a general reduction in mitochondrial protein synthesis rate
(15). Finally, it was also shown in muscle fibres in vivo,
that deficient aminoacylation is important in pathogenesis
of the MELAS syndrome (33).
Whether post-transcriptional modification defects are also
present in mt-tRNALeu(UUR) containing the 3302A>G muta-
tion remains to be determined, however, such a defect
could provide another important disease mechanism, namely
an incorporation of the wrong amino acid into the growing
polypeptide chain. For example, studies in HeLa cybrids car-
rying the 3243A>G mutation showed that mt-tRNALeu(UUR) is
charged properly with leucine, but that the altered modifica-
tion of the wobble base could also lead to mistranslation of
leucine for phenylalanine (16,34). Indeed, formation of trun-
cated peptides and altered peptide fingerprint patterns of
mitochondrial proteins have been demonstrated, for both
the 3243A>G mutation in mt-tRNALeu(UUR) (35–37) and the
7445T>C in tRNASer(UCN) (38). Also, a number of pathogenic
mutations in tRNALeu(UUR) was reported to impede post-
transcriptional modification of the wobble-position uridine
34 (34,39).
In conclusion, a decrease in steady-state levels of
mt-tRNALeu(UUR) carrying the 3302A>G mutation is caused
by inefficient cleavage of the precursor RNA19. This,
together with a defect in aminoacylation due to an altered
structure results in a marked reduction of available Leu-
tRNALeu(UUR) and a severe biochemical defect. Cellular
dysfunction occurs, however, only when the mutation is pre-
sent at almost homoplasmic levels, confirming that the
threshold for this mutation is high. The small accumulation
of RNA19 may contribute to the pathology in cybrid cells,
however, this may be much more important in the patients
muscle, where RNA19 accumulated massively, probably
due to a different processing pathway in this tissue.
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